5 Questions With Bryan Deuber, Biotech Business Development Expert and MPH Student at Johns Hopkins

Photo of Bryan Deuber with his two daughters
Published on : Published by : Sarah Ellinwood

Since Bryan transitioned from the laboratory to business and corporate development at a global CDMO, he has been interested in improving healthcare for patients in and outside of the clinic by working with internal and external stakeholders involved in the next generation biotherapeutics. Over the years, he has gained insight from various sides of the table through his experience at Johns Hopkins, Morgan Stanley, and, more recently, through the sell-side M&A of Paragon Bioservices to Catalent for $1.2B in May 2019. As director of business development at a stealth biotechnology company, he recently interacted across disciplines, from scientists to CEOs. His experience researching opportunities, gathering intelligence, and organizing teams and data for potential deal execution has allowed him to further develop an extensive network within the BioHealth Capital region to improve healthcare and patient outcomes.

Maryland Commerce Supports Research Professorships at Eight Higher Education Institutions

Published on : Published by : BioBuzz Media

The Maryland Department of Commerce joined eight local colleges and universities in endowing a total of $21.2 million to fund a dozen new research professorships. The endowments were made through the Maryland E-Nnovation Initiative (MEI), a state program created to spur basic and applied research in scientific and technical fields at the colleges and universities. The schools raised a total of more than $10.6 million in private funding for each chair and Maryland Commerce approved matching grants of $10.6 million to support the endowments.

Glyscend Therapeutics Announces Initiation of Phase 1 Clinical Trial on the Heels of Preclinical Data Presented at EASD 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy

Published on : Published by : BioBuzz Media

Glyscend, Inc. delivered an oral presentation highlighting preclinical data from a study of its oral proprietary polymer duodenal exclusion therapy during the 57th Annual Meeting of the European Association for the Study of Diabetes on September 28, 2021. Data from earlier results were presented previously this year at the American Diabetes Association 80th Scientific Sessions. Glyscend has also been selected to present at the Obesity Society Annual Meeting in November 2021, focusing on the role of polymer-based duodenal exclusion therapy as an alternative to gastric bypass surgery for the management of obesity.

MyMD Takes on Inflammatory-Related Diseases with MYMD-1

Published on : Published by : Alex Keown

While still in the early stages of development, Baltimore’s MyMD Pharmaceuticals lead therapeutic compound MYMD-1 appears to have the potential to be a pipeline in a pill that can play a role in multiple autoimmune and fibrotic diseases where inflammation plays a key role.

Johns Hopkins Technology Ventures Boosts Maryland Life Sciences

Published on : Published by : Alex Keown

Johns Hopkins Technology Ventures (JHTV) has had a significant impact on the Maryland life sciences ecosystem since its founding in 2014, assisting with hundreds of licensed therapeutics in development and backing nearly 200 startups that have collectively nearly $3 billion in venture capital funding, 30% of which has remained in the state.

5 Questions with Alia Poonawala, Executive Director, Hire Hopkins

Published on : Published by : Andy Eckert

Alia Poonawala is the Executive Director of Hire Hopkins, a design-thinking office out of JHU focused on helping companies get access to the best talent possible from across JHU’s 9 divisions. She forms hiring partnerships with companies who are focused on building diversity and equity in their hiring pipelines.

BHCR passes San Francisco in NIH funding

Johns Hopkins University Peabody Research Library
Published on : Published by : Alex Keown

The National Institutes of Health provides significant funding for drug development research to universities, companies, and organizations. Over the course of 2020, the NIH provided a significant amount of funding to the BioHealth Capital Region.

5 Questions with Chad Schneider, PE, MSE, President & Founder of Root3 Labs

Published on : Published by : Andy Eckert

Mr. Schneider is a mechanical design engineer with over 20 years of engineering experience in the design of complex electromechanical prototypes and products. He earned a BS in mechanical engineering with Honors from the University of Maryland, College Park, and a MSE in mechanical engineering from Johns Hopkins University with a focus on haptics and medical robotics. In 2012, he founded Root3 Labs to focus on practical R&D for the medical device and defense industries.

2020 Virtual BioHealth Capital Region Forum Kicks Off October 19th

Published on : Published by : Steven Surdez

The 6th annual Biohealth Capital Region (BHCR) Forum kicks off on October 19th. This year’s event will be held virtually and will bring together the top biotech and life science executives and expert speakers from across the industry, academia, healthcare, government, finance, and real estate development, among others.

Good News – Featuring Johns Hopkins, Longhorn Vaccines and Diagnostics – Coca-Cola, and More…

Published on : Published by : Steven Surdez

Courtesy of Luke Daum, Chief Scientific Officer and Executive VP at Longhorn Vaccines and Diagnostics Good News – Featuring Johns Hopkins, Longhorn Vaccines and Diagnostics, and More… Across the country, [….]